Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis.

Bluestone JA, Levings MK, Ramsdell FJ et al. (2026)  Front Sci 4:1792210. doi: 10.3389/fsci.2026.1792210

Abstract

Key features of regulatory T cell (Treg) function in
maintaining immune and tissue homeostasis. 

Harnessing the biology of regulatory T cells (Tregs) for therapeutic development is one of medicine’s most promising opportunities to transform disease treatment. Initially viewed simply as guardians against destructive immune responses, we now understand that Tregs are adaptive and highly specialized coordinators of immune tolerance and tissue repair. This strategic roadmap examines how evolving insights into their central role in maintaining tolerance and health can transform therapeutic development across medical specialties. Early efforts to evaluate Treg therapies have proven safe and shown some clinical benefit. The convergence of biological insights and technological advances has the potential to harness and exploit this specialized tolerogenic population by augmenting function through environmental cues and reinforcing tissue-repair capabilities.

Advanced engineering approaches can now endow Treg therapies with antigen-specificity, enforce suppressive programming, and enable off-the-shelf or in vivo gene therapy opportunities. This new class of therapeutics promises to shift treatment paradigms from lifelong management to drug-free durable remissions or even cures for diseases currently requiring chronic immunosuppression. The recognition that dysregulated inflammation underlies countless human diseases opens unprecedented possibilities for treating intractable conditions across specialties—from transplantation and autoimmunity, metabolic disorders and cardiovascular disease, to neurodegeneration and even aging itself. Realizing the potential of Treg-based therapies remains a primary goal for the field, representing a strategic shift from systemic immunosuppression to precision tolerance restoration as a unifying therapeutic paradigm.

Key points

• Regulatory T cells (Tregs) are adaptive, tissue-specialized regulators that maintain immune tolerance and tissue homeostasis, rather than acting only as suppressor cells.
• Dysregulated inflammation underlies many diseases, positioning Treg-based tolerance restoration as a therapeutic strategy beyond traditional transplant and autoimmune indications.
• Early clinical studies have established a foundation of safety and feasibility, while next-generation approaches aim to improve specificity, persistence, stability, and scalability.
• Precision tolerance restoration depends on matching the Treg strategy to disease biology, tissue context, and timing of intervention.
• The field is moving beyond early polyclonal Treg therapies toward more targeted approaches, including antigen-specific, engineered, and potentially off-the-shelf or in vivo strategies, designed to improve precision, persistence, and scalability.

PDF